PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.47%
R&D growth above 1.5x TRAW's 8.13%. Michael Burry would check for spending discipline.
-1.59%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.64%
Operating expenses growth while TRAW reduces costs. John Neff would investigate differences.
14.64%
Total costs growth while TRAW reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
8.11%
D&A change of 8.11% while TRAW maintains D&A. Bruce Berkowitz would investigate efficiency.
-14.78%
EBITDA decline while TRAW shows 0.30% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Operating income decline while TRAW shows 0.30% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-24.66%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-15.16%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
14.88%
Tax expense change of 14.88% while TRAW maintains burden. Bruce Berkowitz would investigate strategy.
-15.16%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
2.78%
EPS growth below 50% of TRAW's 100.00%. Michael Burry would check for structural issues.
2.78%
Diluted EPS growth below 50% of TRAW's 100.00%. Michael Burry would check for structural issues.
19.07%
Share count increase while TRAW reduces shares. John Neff would investigate differences.
19.07%
Diluted share increase while TRAW reduces shares. John Neff would investigate differences.